IL2 and renal cell adenocarcinoma: Since RCC is naturally insensitive to radiotherapy and chemotherapy, cytokine therapy based on interleukin-2 (IL-2) and interferon-α has been the standard treatment since 1990, but the objective response rate of cytokines was only 5%–27%, and the median progression-free survival (PFS) was only 3–5 months, with significant adverse reactions [6].